EpCAM-directed immunotherapy: a novel treatment opportunity for patients with pancreatic cancer {#s1}
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Pancreatic cancer is notorious for its early metastasis and natural resistance to conventional chemotherapy and radiation. However, a recent study by Heeschen and colleagues provides new hope for these patients. The authors reported that epithelial cell adhesion molecule (EpCAM; CD326)-directed immunotherapy effectively eliminates circulating and/or isolated pancreatic cancer stem cells (CSCs) and may be a novel treatment strategy to improve the survival of patients with pancreatic cancer.
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Overexpression and activation of EpCAM in pancreatic CSCs makes EpCAM a promising target for immunotherapy for pancreatic cancer. The bispecific T-cell-engaging antibody construct MT110 was found to simultaneously target EpCAM on tumor cells and the T-cell receptor-CD3 complex on T cells, leading to the author\'s hypothesis that MT110 would be able to eradicate EpCAM-expressing pancreatic cancer cells, including CSCs, by redirecting cytotoxic effector T cells.

Heeschen and colleagues studied the therapeutic effects of MT110 on pancreatic CSCs, involving both established cell lines and primary pancreatic cancer cells, using *in vitro* and *in vivo* models. Compared to the primary tumor cells, the established cell lines were more responsive to MT110-engaged T cells. Moreover, the population of highly tumorigenic CSCs was efficiently targeted by MT110 *in vitro* and *in vivo.* Importantly, metastatic pancreatic cancer cells with a large subpopulation of EpCAM-negative CSCs were less sensitive to MT110 treatment.

Because MT110 has already been tested in clinical trials in patients with other types of tumors, translation of Heeschen and colleagues\' findings into clinical practice, including using CSCs as a biomarker for therapeutic response, could be promising, potentially providing patients with pancreatic cancer a novel treatment opportunity for improved survival.
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